

LIPID, LIPOPROTEINS AND HYPOLIPIDAEMIC THERAPY

**JUNE
18-19
2015**

**OSPEDALE BASSINI
VIA GORKI, 50
CINISELLO BALSAMO
(MI)**

Scientific secretariat
SITeCS – Società Italiana di Terapia Clinica e Sperimentale
via Balzaretti, 7 – 20133 Milano
tel: +39 02 49636373 – fax: +39 02 49633384
e- mail: segreteria@sitecs.it – web www.sitecs.it

Thanks to an unrestricted educational grant from



RATIONALE

In recent years, with regard to the lipid-lowering therapy, therapy with statins has been validated and a series of novel therapeutic approaches has been developed.

If, on the one hand, the pivotal role of statin therapy is confirmed by a large series of studies, the role of the reduction of LDL cholesterol has also been confirmed, as the clinical benefit appears to be independent of the method with which LDL are decreased.

Objectives of this course are:

- 1) to conduct a review of what is known and established in the primary and secondary prevention of cardiovascular disease through the use of lipid-lowering therapy, and indicate possible areas of differentiation between the major therapeutic classes and within them;
- 2) to conduct a survey on new therapeutic approaches, both for rare diseases of lipid metabolism that for the population in general;
- 3) indicate new emerging causal factors that may be of interest in clinical practice.

FACULTY

Alberico Luigi Catapano

Department of Pharmacological and Biomolecular Sciences
University of Milan.

John Chapman

Research Professor
Medical Faculty of the Pierre and Marie Curie University, (UPMC), Paris.

Alberto Corsini

Department of Pharmacological and Biomolecular Sciences
University of Milan.

Liliana Grigore

SISA Atherosclerosis Center, Bassini Hospital - Cinisello B.mo (MI).

Lluís Masana Marín

Internal Medicine Department and Lipid and Cardiovascular Risk Unit
University Hospital Sant Joan - Reus - Spain.

Giuseppe Danilo Norata

Department of Pharmacological and Biomolecular Sciences
University of Milan.

Fabio Pellegatta

SISA Atherosclerosis Center, Bassini Hospital - Cinisello B.mo (MI).

Chairman: Alberico L. Catapano

PROGRAMME

JUNE, 18

- 13.30-14.00** Introduction to the course *Alberico L. Catapano*
14.00-14.30 TG rich lipoproteins, emerging roles in atherosclerosis
Danilo Norata
14.30-14.45 Discussion
14.45-15.30 HDL: quantity or quality? *John Chapman*
15.30-15.45 Discussion

COFFEE BREAK

- 16.00-18.30** Clinical rounds: group split with case discussion
Lluís Masana

VISIT TO THE LIPID CLINIC

Liliana Grigore, Fabio Pellegatta

JUNE, 19

- 9.00-9.30** Guidelines: shall we revise after the IMPROVE IT?
Alberico L. Catapano
9.30-9.45 Discussion
9.45-10-15 Lipid Lowering therapy, the current status *Lluís Masana*
Discussion

COFFEE BREAK

- 10.30-11.00** Current evidence with statins, effects beyond LDL chol
Alberto Corsini
11.00-11.15 Discussion
11.15-11.45 The EAS consensus on statin intolerance *Alberto Corsini*
11.45-12.00 Discussion
12.00-12.30 Future lipid lowering therapies: what is new? *Alberico L. Catapano*
12.30-13.00 Discussion and close of the meeting
13.15 LUNCH AND DEPARTURES